Introduction
Materials and methods
Patients’ data
Statistical and analysis methods
Results
Baseline characteristics
Parameter | Total (n = 164) |
---|---|
Gender (male/female) | 99 (60%)/65 (40%) |
Age, years (≥ 65/ < 65) | 45 (27%)/119 (73%) |
Drinking (yes/no) | 23 (14%)/141 (86%) |
Smoking (yes/no) | 51 (31%)/113 (69%) |
DM (yes/no) | 16 (10%)/148 (90%) |
Hypertension (yes/no) | 68 (41%)/96 (59%) |
Anemia (yes/no) | 55 (34%)/109 (66%) |
Hypoalbuminemia (yes/no) | 10 (6.0%)/154 (94%) |
Surgical approach (Partial nephrectomy/ Radical nephrectomy) | 22 (13%)/142 (87%) |
Renal dysfunction (yes/no) | 8 (5.0%)/156 (95%) |
Tumor number (> = 2/1) | 4 (2.0%)/160 (98%) |
Site (left/right) | 84 (51%)/80 (49%) |
Pathologic T stage (T1/T2/T3/T4) | 134 (82%)/17 (10%)/10 (6%)/3 (2.0%) |
G grade (1/2/3/4) | 99 (60%)/45 (27%)/7 (4.0%)/6 (4.0%) |
Tumor necrosis (yes/no) | 6 (4.0%)/158 (96%) |
Tumor hemorrhage | 12 (7.0%)/152 (93%) |
Lymphatic and microvascular infiltration | 7 (4.0%)/157 (96%) |
PNI (> 47.40/ < 47.40) | 119 (73%)/45 (27%) |
MLR (> 0.31/ < 0.31) | 57 (35%)/107 (65%) |
PLT (> 245/ < 245) | 16 (10%)/148 (90%) |
PMP score (0/1/2/3) | 7 (4.0%)/24 (15%)/49 (30%)/84 (51%) |
Parameter | Total (n = 164) |
---|---|
Age, years | 56.72 ± 11.78 |
Tumor size, cm | 4.00(3.00, 5.00) |
Serum creatinine, mg/dl | 73.60(61.63, 88.28) |
BUN, mg/dl | 5.81(4.84, 6.81) |
ALT, U/l | 18.50(13.00, 30.00) |
AST, U/l | 18.00(15.00, 23.00) |
Hemoglobin, g/dl | 129.16 ± 17.87 |
MLR | 0.27(0.21, 0.36) |
PLT | 172.43 ± 64.14 |
PNI | 50.78 ± 6.17 |
Patient characteristics and clinical outcomes based on PNI-MLR-PLT score
Parameters | PMP score | ||||
---|---|---|---|---|---|
0 (n = 7) | 1 (n = 24) | 2 (n = 49) | 3 (n = 84) | P value | |
Gender | 0.728 | ||||
Male (n = 99) | 4 (2.0%) | 17 (10%) | 29 (17%) | 49 (30%) | |
Female (n = 65) | 3 (2.0%) | 7 (4.0%) | 20 (12%) | 35 (21%) | |
Age (years) | 0.051 | ||||
< 65 (n = 119) | 3 (2.0%) | 14 (9.0%) | 35 (21%) | 67 (41%) | |
> 65 (n = 45) | 4 (2.0%) | 10 (6.0%) | 14 (9.0%) | 17 (10%) | |
Smoking | 0.065 | ||||
Yes (n = 51) | 2 (1.0%) | 13 (8.0%) | 12 (7.0%) | 24 (15%) | |
No (n = 113) | 5 (3.0%) | 11 (7.0%) | 37 (23%) | 60 (37%) | |
Drinking | 0.774 | ||||
Yes (n = 23) | 1 (1.0%) | 5 (3.0%) | 6 (4.0%) | 11 (7.0%) | |
No (n = 141) | 6 (4.0%) | 19 (12%) | 43 (26%) | 73 (45%) | |
Hypertension | 0.603 | ||||
Yes (n = 68) | 4 (2.0%) | 11 (7.0%) | 22 (13%) | 31 (19%) | |
No (n = 96) | 3 (2.0%) | 13 (8.0%) | 27 (16%) | 53 (32%) | |
DM | 0.410 | ||||
Yes (n = 16) | 0 (0) | 4 (2.0%) | 3 (2.0%) | 9 (5.0%) | |
No (n = 148) | 7 (4.0%) | 20 (12%) | 46 (28%) | 75 (46%) | |
Anemia | < 0.001 | ||||
Yes (n = 55) | 7 (4.0%) | 14 (9.0%) | 16 (10%) | 18 (11%) | |
No (n = 109) | 0 (0) | 10 (6.0%) | 33 (20%) | 66 (40%) | |
Renal dysfunction | 0.033 | ||||
Yes (n = 8) | 0 (0) | 4 (2.0%) | 2 (1.0%) | 2 (1.0%) | |
No (n = 156) | 7 (4.0%) | 20 (12%) | 47 (29%) | 82 (50%) | |
ALT | 0.387 | ||||
> 13.5 (n = 117) | 3 (2.0%) | 17 (10%) | 35 (21%) | 62 (38%) | |
< 13.5 (n = 47) | 4 (2.0%) | 7 (4.0%) | 14 (9.0%) | 22 (13%) | |
AST | 0.652 | ||||
> 19.5 (n = 68) | 2 (1.0%) | 8 (5.0%) | 20 (12%) | 38 (23%) | |
< 19.5 (n = 96) | 5 (3.0) | 16 (10%) | 29 (18%) | 46 (28%) | |
BUN | 0.171 | ||||
> 7.325 (n = 27) | 2 (1.0%) | 7 (4.0%) | 5 (3.0%) | 13 (8.0%) | |
< 7.325 (n = 137) | 5 (3.0%) | 17 (10%) | 44 (27%) | 71 (43%) | |
PLT | |||||
> 245 (n = 16) | 7 (4.0%) | 3 (2.0%) | 6 (4.0%) | 0 (0) | < 0.001 |
< 245 (n = 148) | 0 (0) | 21 (13%) | 43 (26%) | 84 (51%) | |
MLR | |||||
> 0.31 (n = 57) | 7 (4.0%) | 23 (14%) | 27 (16%) | 0 (0) | < 0.001 |
< 0.31 (n = 107) | 0 (0) | 1 (1.0%) | 22 (13%) | 84 (51%) | |
PNI | |||||
> 47.40 (n = 119) | 0 (0) | 2 (1.0%) | 33 (20%) | 84 (51%) | < 0.001 |
< 47.40 (n = 45) | 7 (4.0%) | 22 (13%) | 16 (10%) | 0 (0) | |
Tumor number | 0.739 | ||||
> = 2 (n = 4) | 0 (0) | 0 (0) | 1 (1.0%) | 3 (2.0%) | |
< 2 (n = 160) | 7 (4.0%) | 24 (15%) | 48 (29%) | 81 (49%) | |
Site | 0.219 | ||||
Left (n = 84) | 2 (1.0%) | 9 (6.0%) | 25 (15%) | 48 (30%) | |
Right (n = 80) | 5 (3.0%) | 15 (9.0%) | 24 (15%) | 36 (22%) | |
Tumor size (cm) | < 0.001 | ||||
> 7.3 (n = 13) | 3 (2.0%) | 4 (2.0%) | 5 (3.0%) | 1 (1.0%) | |
< 7.3 (n = 151) | 4 (2.0%) | 20 (12%) | 44 (27%) | 83 (51%) | |
Grade | < 0.001 | ||||
1 (n = 99) | 3 (2.0%) | 12 (7.0%) | 28 (17%) | 56 (34%) | |
2 (n = 45) | 0 (0) | 7 (4.0%) | 16 (10%) | 22 (13%) | |
3 (n = 7) | 1 (1.0%) | 2 (1.0%) | 2 (1.0%) | 2 (1.0%) | |
4 (n = 6) | 3 (2.0%) | 2 (1.0%) | 1 (1.0%) | 0 (0) | |
T stage | < 0.001 | ||||
1 (n = 134) | 2 (1.0%) | 14 (9.0%) | 41 (25%) | 77 (47%) | |
2 (n = 17) | 3 (2.0%) | 6 (4.0%) | 6 (4.0%) | 2 (1.0%) | |
3 (n = 10) | 1 (1.0%) | 2 (1.0%) | 2 (1.0%) | 5 (3.0%) | |
4 (n = 3) | 1 (1.0%) | 2 (1.0%) | 0 (0) | 0 (0) | |
Tumor hemorrhage | 0.781 | ||||
Yes (n = 12) | 0 (0) | 1 (1.0%) | 4 (2.0%) | 7 (4.0%) | |
No (n = 152) | 7 (4.0%) | 23 (14%) | 45 (27%) | 77 (47%) | |
Tumor necrosis | 0.424 | ||||
Yes (n = 6) | 0 (0) | 0 (0) | 1 (1.0%) | 5 (3.0%) | |
No (n = 158) | 7 (4.0%) | 24 (15%) | 48 (30%) | 79 (48%) | |
Lymphatic and microvascular infiltration | < 0.001 | ||||
Yes (n = 7) | 1 (1.0%) | 4 (2.0%) | 0 (0) | 2 (1.0%) | |
No (n = 157) | 6 (4.0%) | 20 (12%) | 49 (30%) | 82 (50%) |
Cox regression analysis and predictive efficacy of PNI-MLR-PLT score
Parameters | OS | MFS | ||
---|---|---|---|---|
HR | P | HR | P | |
Gender | 0.61(0.30–1.26) | 0.181 | 1.19(0.27–5.31) | 0.824 |
Age | 1.18(1.08–1.30) | < 0.001 | 1.06(0.99–1.14) | 0.085 |
Smoking | 0.90(0.44–1.84) | 0.768 | 1.56(0.35–6.99) | 0.561 |
Drinking | 0.73(0.33–1.64) | 0.449 | 0.04(0.00–304.09) | 0.476 |
Hypertension | 0.82(0.41–1.64) | 0.576 | 9.35(1.12–77.75) | 0.039 |
DM | 0.85(0.30–2.43) | 0.765 | 1.82(0.22–15.11) | 0.581 |
Anemia | 0.16(0.03–0.81) | 0.027 | 5.26(1.02–27.11) | 0.047 |
Renal dysfunction | 2.89(0.36–23.51) | 0.321 | 0.05(0.00–1.06E) | 0.723 |
ALT | 0.99(0.94–1.04) | 0.584 | 0.99(0.95–1.04) | 0.727 |
AST | 0.98(0.90–1.07) | 0.657 | 0.90(0.77–1.05) | 0.170 |
BUN | 1.12(0.97–1.29) | 0.132 | 1.10(0.91–1.33) | 0.310 |
Tumor number | 0.05(0.00–14,033,642.09) | 0.760 | 0.05(0.00–2.67E) | 0.767 |
Tumor size | 13.33(3.33–53.35) | < 0.001 | 17.39(3.89–77.75) | < 0.001 |
PMP score (2 + 3/0 + 1) | 0.07(0.01–0.34) | 0.001 | 0.08(0.02–0.40) | 0.002 |
T stage (III + IV/ I + II) | 15.61(3.87–62.91) | < 0.001 | 20.80(4.63–93.38) | < 0.001 |
Grade (III + IV/I + II) | 100.78(12.37–820.98) | < 0.001 | 100.91(12.05–845.06) | < 0.001 |
Tumor hemorrhage | 0.05(0.00–9123.80) | 0.618 | 0.04(0.00–15,007.24) | 0.632 |
Tumor necrosis | 0.05(0.00–420,311.62) | 0.708 | 0.05(0.00–1.99E) | 0.733 |
Lymphatic and microvascular infiltration | 3.49(0.43–28.40) | 0.242 | 9.76(1.89–50.32) | 0.006 |
Parameters | OS | MFS | ||
---|---|---|---|---|
HR | P | HR | P | |
Age | 19.78(1.55–252.32) | 0.022 | - | - |
Hypertension | - | - | - | 0.060 |
Anemia | - | 0.222 | - | 0.888 |
Tumor size | - | 0.824 | - | 0.295 |
PMP score (2 + 3/0 + 1) | 0.11(0.02–0.68) | 0.018 | 0.10(0.01–0.93) | 0.043 |
T stage (III + IV/ I + II) | 4.66(1.90–24.11) | 0.027 | 14.62(1.30–164.66) | 0.030 |
Grade (III + IV/I + II) | 39.45(4.41–352.80) | 0.001 | 56.50(5.08–628.60) | 0.001 |
Lymphatic and microvascular infiltration | - | - | - | 0.061 |